This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (8)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • HIV/AIDS  • Retinal/ Chorioretinal Disorders  • Infectious Diseases  • Alert me on articles by topic

Arch Ophthalmol. 2004;122:1040-1042.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Since the introduction of highly active antiretroviral therapy (HAART) in 1996, there has been a dramatic change in the AIDS epidemic in industrialized nations.¹ Highly active antiretroviral therapy consists of combination antiretroviral therapy, typically with 3 or more drugs, and generally includes either a protease inhibitor or a nonnucleoside reverse transcriptase inhibitor. By suppressing human immunodeficiency virus (HIV) replication for sustained periods of time, HAART can lead to improvements in immune function (immune recovery) and restoration of immunity to specific pathogens.² As a consequence, the incidence of opportunistic infections has declined, as has the mortality associated with AIDS,¹ resulting in an increased prevalence of patients alive with AIDS. If there is sufficient sustained immune recovery, secondary prophylaxis ("maintenance therapy"), such as those for Pneumocystis carinii pneumonia and cytomegalovirus (CMV) retinitis, can be discontinued without relapse of the disease.^3-4

Prior to the introduction of HAART, numerous series described the ocular complications . . . [Full Text of this Article]

Douglas A. Jabs, MD, MBA

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

AIDS and Ophthalmology, 2008
Jabs
Arch Ophthalmol 2008;126:1143-1146.
FULL TEXT